

**Frank Lezoualc'h**

Frank Lezoualc'h received his PhD in molecular endocrinology from the University Pierre & Marie Curie, Paris, and completed a postdoctoral fellowship at the Max-Planck Institute in Munich. He was appointed Director of Research at Inserm, University Paris-Sud, in 2005 and became the head of the laboratory "Signaling and Pathophysiology of Heart Failure and Aging" at Inserm, Toulouse University, in 2010. His research focuses on intracellular signalosomes activated by acute or chronic cardiac stress, which drive pathological cardiac remodeling. He aims to identify relevant targets for the treatment of heart failure and aging. His work has led to the characterization of novel potential therapeutic targets, such as EPAC and Carabin, as well as promising drug candidates, including pharmacological inhibitors of EPAC.